Aktienanalyse zu Grifols SA (GRFS)GRFSGrifols SA

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use. It operates in the Healthcare sector.

Grifols SA (GRFS) is currently priced at 7.64, with a forward P/E ratio of 5.81, indicating potential undervaluation. However, the company faces significant operational risks highlighted by recent regulatory restrictions in Canada, which could impact its reputation and operations. The RSI is at 68.25, suggesting it is nearing overbought territory, which could lead to a pullback. The main risk is the 986.97% increase in hedge fund selling, indicating a lack of confidence among institutional investors.

4 analysts cover GRFS: 3 rate it Buy, 0 Hold and 1 Sell.